Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Mohamed Amine Bekadja, Ariane Boumendil, Sr., PhD, Didier Blaise, MD, Patrice Chevalier, MD PhD, Karl S Peggs, MD PhD, Gilles Salles, MD PhD, Sebastian Giebel, Sr., Jürgen Finke, Sr., MD PhD, William Arcese, MD PhD, Noel Milpied, Hervé Finel, Sr., MD PhD, Norbert Claude Gorin, Sr., MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-133900

Published: 2020

Journal Articles

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Lorna Neill, Strachan C Mackenzie, MBBS, BSc, MRCP, Maria A V Marzolini, William Townsend, MRCP,MDFRCPath, Kirit M. Ardeshna, Kate Cwynarski, Surjo De, Vanya Gant, Lhara Mure, Sara McElduff, Chantelle Hughes, Karl S Peggs, MD PhD, Claire Roddie, PhD MD, Maeve A O'Reilly, MBBCHBAO

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-138865

Published: 2020

Journal Articles

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137768

Published: 2020

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Paul Michael Maciocia, BSc,MBBS,MRCP, Patrycja Wawrzyniecka, MSc, Brian Philip, PhD, Ida Ricciardelli, PhD, Ayse U. Akarca, BSc, Shimobi Onuoha, PhD, David Cole, PhD, Andrew Sewell, PhD, Karl S Peggs, MD, David C. Linch, MD MRCP, MB BCh, BA, Teresa Marafioti, MD, Martin A Pule, MD PhD

Blood (2016) 128 (22): 811.

https://doi.org/10.1182/blood.V128.22.811.811

Published: 2016

Journal Articles

Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD

Rob S Sellar, MBBS, Frederick Arce Vargas, PhD, Jake Henry, Simon Thomas, PhD, Alka Stansfield, Stephanie Verfuerth, PhD, Sarah C Charrot, MBBS, Rachael E Hough, MD, Sergio A Quezada, PhD, Kirsty J Thomson, MD, Stephen Mackinnon, MD, Karl S Peggs, MD

Blood (2013) 122 (21): 4524.

https://doi.org/10.1182/blood.V122.21.4524.4524

Published: 2013

Journal Articles

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

Kile Green, BSc(Hons), Rob Sellar, MD, Laura Jardine, MD, Janice Ward, Paul Ferguson, MD, Pip Nicolson, MD, Kim Pearce, PhD, Venetia Bigley, MD, PhD, Graham Jackson, MD, Sandeep Nagra, MD, Anne M Dickinson, PhD, Kirsty Thomson, MD, Stephen Mackinnon, MD, Charles Craddock, MD, Matthew P. Collin, MD, PhD, Karl S Peggs, MD

Blood (2013) 122 (21): 4540.

https://doi.org/10.1182/blood.V122.21.4540.4540

Published: 2013

Journal Articles

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Jaimal Kothari, MD, Antonia Ljubic, BSc, Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Andres E. Virchis, MD, Jonathan Lambert, MD, Anthony H Goldstone, MD, David C Linch, MD FMedSci, Kirit M Ardeshna, MD

Blood (2011) 118 (21): 2025.

https://doi.org/10.1182/blood.V118.21.2025.2025

Published: 2011

Journal Articles

Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma

Kirsty Thomson, Irfan Kayani, Kirit M Ardeshna, MD, Emma Morris, MD, Rachael Hough, Anthony H Goldstone, MD, David C Linch, MD FMedSci, Karl S Peggs, MD

Blood (2011) 118 (21): 336.

https://doi.org/10.1182/blood.V118.21.336.336

Published: 2011

Journal Articles

A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning

William Townsend, Ailsa Holroyd, Rachel M Pearce, Stephen Mackinnon, MD, Anthony H. Goldstone, FRCP, FRCPath, David C Linch, MD FMedSci, Karl S Peggs, MD, Kirsty Thomson, MD, Mervyn Singer, Prakesh Naik, David Howell, Emma Morris, MD

Blood (2011) 118 (21): 146.

https://doi.org/10.1182/blood.V118.21.146.146

Published: 2011

Journal Articles

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Karl S Peggs, MD, Kirsty Thomson, MD, Edward Samuel, BSc, MSc, Gemma Dyer, Julie Armoogum, Kwok Pang, BSc, MSc, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 44.

https://doi.org/10.1182/blood.V114.22.44.44

Published: 2009

Journal Articles

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Noha Chowdhry, Stephanie Verfuerth, PhD, Panos Kottaridis, Anthony H. Goldstone, FRCP, FRCPath, Kirit Ardeshna, MD, David Linch, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD

Blood (2009) 114 (22): 200.

https://doi.org/10.1182/blood.V114.22.200.200

Published: 2009

Journal Articles

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

Stephen P Robinson, Anna Sureda, Carmen Canals, Sr., Jean-Paul Vernant, Noel-Jean Milpied, PhD, Jürgen Finke, Johan Maertens, Jean-Pierre Jouet, MD, Charles F. Craddock, BM, MRCP, MRCPath, Karl S Peggs, MD, Steven Le Gouill, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 457.

https://doi.org/10.1182/blood.V112.11.457.457

Published: 2008

Journal Articles

CMV-Specific T Cell Immunotherapy Promotes Restoration of Durable Functional Immunity in High Risk Patients Following Allogeneic Stem Cell Transplantation

Karl S Peggs, MD, Stephanie Verfuerth, PhD, Arnold Pizzey, Christine Chow, Kirsty Thomson, MD, Stephen Mackinnon, MD

Blood (2008) 112 (11): 352.

https://doi.org/10.1182/blood.V112.11.352.352

Published: 2008

Journal Articles

Cytomegalovirus (CMV)-Specific CD8+ T Cells Are Associated with Control of Viral Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to Be Functionally Active.

Stephanie Verfuerth, PhD, Karl S Peggs, MD, Arnold Pizzey, Noha Chowdhry, Stephen Mackinnon, MD

Blood (2008) 112 (11): 2213.

https://doi.org/10.1182/blood.V112.11.2213.2213

Published: 2008

Journal Articles

Dissociation of Systemic and Local Anti-Tumor Immunity Following Depletion of Regulatory T Cells Limits Therapeutic Activity in Established Tumors.

Karl S. Peggs, MD, Sergio A. Quezada, PhD, Tyler R. Simpson, James P. Allison, PhD

Blood (2007) 110 (11): 286.

https://doi.org/10.1182/blood.V110.11.286.286

Published: 2007

Journal Articles

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Kirsty J. Thomson, MD, Emma C. Morris, MD, Don Milligan, MD, Gordon Cook, MD, Jim Cavet, MD, Charles Craddock, MD, Ann Hunter, MD, Steve Schey, MD, Anne Parker, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Karl S. Peggs, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 401.

https://doi.org/10.1182/blood.V106.11.401.401

Published: 2005

Journal Articles

Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: No Increase in Relapse with Alemtuzumab-Depleted Grafts.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Emma C. Morris, MD, Asim Khwaja, MD, David C. Linch, MD, Anthony H. Goldstone, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 2053.

https://doi.org/10.1182/blood.V106.11.2053.2053

Published: 2005

Journal Articles

Dose-Escalated Donor Lymphocyte Infusions Post Allogeneic Transplantation in Non-Hodgkin’s Lymphoma.

Adrian J.C. Bloor, MD, PhD, Kirsty Thomson, MD, Nichola Cooper, MD, Karl S. Peggs, MD, PhD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 2013.

https://doi.org/10.1182/blood.V106.11.2013.2013

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

NARROW

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma

A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

CMV-Specific T Cell Immunotherapy Promotes Restoration of Durable Functional Immunity in High Risk Patients Following Allogeneic Stem Cell Transplantation

Cytomegalovirus (CMV)-Specific CD8+ T Cells Are Associated with Control of Viral Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to Be Functionally Active.

Dissociation of Systemic and Local Anti-Tumor Immunity Following Depletion of Regulatory T Cells Limits Therapeutic Activity in Established Tumors.

Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: No Increase in Relapse with Alemtuzumab-Depleted Grafts.

Dose-Escalated Donor Lymphocyte Infusions Post Allogeneic Transplantation in Non-Hodgkin’s Lymphoma.

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only